Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain King Faisal Specialist Hospital and Research Center – Riyadh RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King […]
Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
King Faisal Specialist Hospital and Research Center – Riyadh

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells. This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread. This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

Dr. Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Centre in Jeddah and the lead researcher, stated: “This discovery paves the way for the development of more effective treatments for the deadliest malaria strain, Plasmodium falciparum.” Also, this study enhances the scientific community’s understanding of the disease’s progression and its interaction with the human immune system, thereby strengthening efforts to combat this widespread malaria parasite prevalent in Africa.

Furthermore, the research demonstrated that the PfAP2-MRP gene regulates the production of genetically diverse protein receptors, allowing the parasite to evade the host’s immune system. This mechanism plays a significant role in the global spread of malaria and underscores the gene’s importance in developing future therapeutic strategies.

Published in the prestigious journal “Nature” this noteworthy study is part of a close collaboration between KFSH&RC and KAUST to engage in innovative research activities aimed at not only improving the diagnosis of microbes, bacteria, and parasites, but also underscores a global effort to combat pathogens and improve human health.

King Faisal Specialist Hospital and Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2023, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba

CONTACT INFORMATION 

For more information please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232

GlobeNewswire Distribution ID 9031968

Previous Article

‫باحثون في “التخصصي” وجامعة “كاوست” يكتشفون جينًا مسؤولاً عن تكاثر أخطر أنواع الملاريا

Next Article

Curia Receives 2024 CDMO Leadership Award

Related Posts

‫شبكة تلفزيون الصين الدولية (CGTN): الصين ستواصل مساهمتها في تعزيز السلام والتنمية العالميينب

بكين, 2 يناير / كانون الثاني 2023/PRNewswire/ — أشار الرئيس الصيني شي جين بينغ -في كلمته التي ألقاها يوم السبت للتهنئة بحلول العام الجديد 2023- إلى أنّ الصين دولة تربطها بدول العالم علاقات وثيقة، وقال إنّه -خلال العام الماضي- استقبل الكثير من الأصدقاء القدامى والجدد من قادة العالم في بكين، بالإضافة إلى سفره إلى خارج البلاد […]

Qoyod achieves the Best Place to Work certification in Saudi for 2022

RIYADH, Saudi Arabia, Nov. 30, 2022 /PRNewswire/ — Qoyod, the Best Accounting Solutions Provider in KSA FY2022 specialized in developing state-of-the-art cloud computing technology that transforms traditional accounting into cloud computing, has recently been recognized as one of the best places to work in Saudi for 2022. This acknowledges Qoyod’s commitment towards fostering an environment […]

Leading Dubai-Based Carrier Selects GEP SMART Software To Elevate Its Procurement Capabilities

— GEP’s unified procurement platform will support the airline’s source-to-pay function to build closer relationships with suppliers and deliver greater value to customers DUBAI, U.A.E., Oct. 12, 2021 /PRNewswire/ — GEP®, a leading provider of procurement software and services to Fortune 500 and Global 2000 enterprises worldwide, announced today that a leading Dubai-based carrier has selected GEP SMART™, […]

Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints

REGULATED INFORMATION  INSIDE INFORMATION Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints Mont-Saint-Guibert, Belgium – 7 June 2021, 7:00 am CET / 1:00 am ET – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced […]